• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Bristol-Myers Squibb Company - Articles and news items

collabs

Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Bristol-Myers’ Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy…

smc

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

cormorant pharmaceuticals

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The acquisition gives Bristol-Myers Squibb full rights to Cormorant Pharmaceuticals’ HuMax-IL8 antibody programme…

enadenotucirev

BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients…

sickle cell disease

BMS in sickle cell partnership to help treat Angolan children

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The Angola Sickle Cell Initiative and Bristol-Myers Squibb are teaming up to provide children with sickle cell disease in Angola with Droxia…

nivolumab

NICE recommends nivolumab + ipilimumab for advanced melanoma

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

The NHS will receive a discount on the combination treatment agreed between Bristol-Myers Squibb and the Department of Health…

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Industry news / 8 June 2016 / Mandy Parrett, Editorial Assistant

Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

BMS and MD Anderson in lung cancer research collaboration

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients…

opdivo

BMS presents new data for Opdivo at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)…

mrcc

Data support Opdivo as new standard of care in mRCC, says GlobalData

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)…

empliciti

EC approves Empliciti as combination therapy for multiple myeloma

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy…

nsclc

NICE says ‘no’ to Opdivo for non-squamous NSCLC

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +